The Future of Neoadjuvant Immunotherapy in MIBC
Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
EP: 1.Case Presentation: A 75-Year-Old Woman with Muscle-Invasive Bladder Cancer (MIBC)
EP: 2.Eligibility for Cisplatin Therapy in Patients with MIBC
EP: 3.Available Adjuvant Therapy Options for Patients with Stage II or III MIBC after Cystectomy
EP: 4.Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274
EP: 5.CheckMate 274: Data Updates in MIBC from GU ASCO, ASCO, and ESMO 2022
EP: 6.Factors for Consideration when Choosing an Adjuvant Therapy Regimen for Patients with MIBC
EP: 7.Critical Unmet Needs for Patients with MIBC
EP: 8.The Future of Neoadjuvant Immunotherapy in MIBC
NIAGARA Trial Results Show Durvalumab/Chemo Improves EFS, OS in Cisplatin-Eligible MIBC
September 15th 2024In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.
Read More
Extended Follow-Up Bolsters Adjuvant Pembrolizumab DFS Rate in MIUC
September 15th 2024Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.
Read More
